38MO IND.236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)
Titel:
38MO IND.236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)
Auteur:
Mates, M. Bedard, P. Hilton, J. Gelmon, K.A. Srikanthan, A. Awan, A. Song, X. Lohrisch, C. Robinson, A. Tu, D. Hagerman, L. Zhang, S. Drummond-Ivars, N. Li, I. Rastgou, L. Edwards, J. Bray, M. Rushton, M. Gaudreau, P-O.